BCL2 and non-small cell lung carcinoma: Lu et al. found that resveratrol inhibited NSCLC cell proliferation via miR-345- and miR-498-regulated MAPK/CFO and Akt/BCL2 signaling pathways by directly targeting MAPK1 and PIK3R1, respectively, which increased the sensitivity of NSCLC cells to gefitinib and induced apoptosis [103].